FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to indolin-2-one derivatives.
EFFECT: said compounds can be used for treating CNS diseases associated with positive (psychosis) and negative symptoms of schizophrenia, abuse of drugs, alcohol and drug addiction, obsessive-compulsive disorders, cognitive disorders, bipolar disorders, mood disorders, deep depression, therapeutically resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative diseases, sleep disorders, chronic fatigue syndrome, stiffness, inflammatory diseases, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, arthritis, autoimmune diseases, viral and fungal infections, cardiovascular diseases, ophthalmic and inflammatory retinal diseases and disturbed equilibrium, epilepsy and CNS development disorders accompanying epilepsy.
25 cl, 3 tbl, 46 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | 2014 |
|
RU2666532C2 |
| INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-C]PYRIDIN-2-ONE DERIVATIVES | 2015 |
|
RU2697512C2 |
| OXYINDOLE DERIVATIVES POSSESSING AGONIST ACTIVITY ON MOTILIN RECEPTOR | 2010 |
|
RU2533116C2 |
| 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | 2014 |
|
RU2665580C2 |
| PYRROL[2,3-B]PYRAZINES AS SYK INHIBITORS | 2013 |
|
RU2656853C2 |
| BENZOTHIAZOLE COMPOUNDS AND METHODS FOR THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 2018 |
|
RU2778370C2 |
| ARYLETHINYL DERIVATIVES | 2011 |
|
RU2573560C2 |
| DERIVATIVES OF N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDES AND THEREOF APPLICATION AS PDE10A INHIBITORS | 2011 |
|
RU2562066C2 |
| KYNURENINE-3-MONOOXYGENASE INHIBITORS | 2009 |
|
RU2523448C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
